Coalescing single-cell genomes and transcriptomes to decode breast cancer progression
- PMID: 40912251
- PMCID: PMC12416759
- DOI: 10.1016/j.cell.2025.08.012
Coalescing single-cell genomes and transcriptomes to decode breast cancer progression
Abstract
Understanding epithelial lineages of breast cancer and genotype-phenotype relationships requires direct measurements of the genome and transcriptome of the same single cells at scale. To achieve this, we developed wellDR-seq, a high-genomic-resolution, high-throughput method to simultaneously profile the genome and transcriptome of thousands of single cells. We profiled 33,646 single cells from 12 estrogen-receptor-positive breast cancers and identified ancestral subclones in multiple patients that showed a luminal hormone-responsive lineage, indicating a potential cell of origin. In contrast to bulk studies, wellDR-seq enabled the study of subclone-level gene-dosage relationships, which showed near-linear correlations in large chromosomal segments and extensive variation at the single-gene level. We identified dosage-sensitive and dosage-insensitive genes, including many breast cancer genes as well as sporadic copy-number aberrations in non-cancer cells. Overall, these data reveal complex relationships between copy number and gene expression in single cells, improving our understanding of breast cancer progression.
Keywords: DNA copy number; aneuploidy; breast cancer genomics; breast cancer progression; gene dosage effects; single-cell DNA and RNA sequencing; single-cell multiomics; single-cell sequencing; tumor evolution; wellDR-seq.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A US patent (PCT/US2023/074051) related to the wellDR-seq method has been filed.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
